WITHDRAWN: TREATMENT FAILURE AND EMPIRIC ANTIBIOTIC CHOICE FOR HOSPITALIZED PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA: Β-LACTAM/Β-LACTAMASE INHIBITOR COMBINED WITH MACROLID OR FLUOROQUINOLONE ALONE?
DOI:
https://doi.org/10.29121/granthaalayah.v7.i7.2019.778Keywords:
Lactate Dehydrogenase, Lymphocytes, Neutrohils, PneumoniaAbstract [English]
Background
A considerable percentage of empirical antibiotic treatment fails in hospitalized patients with community-acquired pneumonia (CAP). β-lactams and macrolid (BLM) combination or respiratory fluoroquinolones (FQ) are the most frequently used in these patients. The aim of the present study is to compare the treatment failure (TF) rates in BLM and FQ treatment and to analyze the predictive factors of TF.
Method
Hospitalized patients who were initially treated with either BLM or FQ were included retrospectively and treatment results of the two regimens were compared.
Results
Of the 144 patients included in the study, the mean age was 67±16 and 102 (71%) were male. Each group constituted of 72 patients. Antibiotic selection did not alter TF rates, length of stay (LOS) and 30-day mortality. Baseline higher levels of leucocytes, neutrophils to lymphocytes ratio (NLR), C-reactive protein (CRP), BUN/albumin, lactate dehydrogenase/aspartat aminotransferase (LDH/AST) levels and pneumonia severity index (PSI) scores were detected as predictors of TF.
Conclusion
Empirical treatments with either BLM or FQ do not correlate with TF, LOS and 30-day mortality. NLR, BUN/albumin and LDH/AST may suggest TF. These inexpensive and easily-reachable parameters have the potential as predictors of the treatment outcome in CAP.
Notices of retraction
Akyil, F. T., Bekir, S. A., Gungor, A., Akyuz, K., Kose, N., Turker, H., Akyil, M., & Sevim, T. (2019). TREATMENT FAILURE AND EMPIRIC ANTIBIOTIC CHOICE FOR HOSPITALIZED PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA: Β-LACTAM/Β-LACTAMASE INHIBITOR COMBINED WITH MACROLID OR FLUOROQUINOLONE ALONE?. International Journal of Research -GRANTHAALAYAH, 7(7), 360-369. https://doi.org/10.29121/granthaalayah.v7.i7.2019.778
Article retracted by : Editor
Reason(s) for retraction : Author's conflicts of interest
Downloads
References
Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Jeune I Le, Macfarlane JT, Read RC, Roberts HJ, Levy ML, Wani M, Woodhead MA. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009;64(Suppl. 3):iii1-55. DOI: https://doi.org/10.1136/thx.2009.121434
Pfuntner A, Wier LM, Steiner C; Most Frequent Conditions in U.S. Hospitals, 2010:Statistical Brief #148. 2013 Jan. In: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2006 Feb-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK127490/
US Centers for Disease Control and Prevention. FastStats: leading causes of death. http://www.cdc
.gov/nchs/fastats/leading-causes-of-death.htm. Accessed September 4, 2015.
Mandell LA, Wunderink RG, Anzueto A, Barlett JG, Campbell D, Dean NC, Dowell SF, File TM, Musher DM, Niederman MS, Torres A, Whitney CG. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community acquired pneumonia in adults. Clin Infect Dis 2007;44 Suppl 2:S27-72. DOI: https://doi.org/10.1086/511159
Menéndez R, Torres A, Zalacaín R, Martin Villasclaras JJ, Borderias L, Benitez Moya JM, Ruiz-Manzano J, Rodriguez de Castro F, Blanquer J, Perez D, Puzo C, Sanchez Gascon F, Gallardo J, Alvarez C, Molinos L, Nuumofail Group. Risk factors of treatment failure in community acquired pneumonia: Implications for disease outcome. Thorax 2004;59:960-5. DOI: https://doi.org/10.1136/thx.2003.017756
Nie XM, Li YS, Yang ZW, Wang H, Jin SY, Jiao Y, Metersky ML, Huang Y. Initial empiric antibiotic therapy for community-acquired pneumonia in Chinese hospitals. Clinical Microbiology and Infection, 2018;24(6), 658-e1. DOI: https://doi.org/10.1016/j.cmi.2017.09.014
Kılınç O, Ece T, Arman D. Türk Toraks Derneği pnömoni tanı ve tedavi uzlaşı raporu. Türk Toraks Derg. 2009;10(Suppl. 6):1-24.
Postma DF, van Werkhoven CH, van Elden LJ, Thijsen SF, Hoepelman Al, Kluytmans JA, Boersma WG, Compaijen CJ, van der Wall E, Prins JM, Oosterheert JJ, Bonten MJ; CAP-START Study Group. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med 2015;372:1312–23. DOI: https://doi.org/10.1056/NEJMoa1406330
Vardakas KZ, Siempos II, Grammatikos A, Athanassa Z, Korbila IP, Falagas ME. Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. Canadian Medical Association Journal. 2008;179(12):1269-77. DOI: https://doi.org/10.1503/cmaj.080358
Ott SR, Hauptmeier BM, Ernen C, Lepper PM, Nüesch E, Pletz MW, Hecht J, Welte T, Bauer TT. Treatment failure in pneumonia: Impact of antibiotic treatment and cost analysis. Eur Respir J 2012;39:611-8. DOI: https://doi.org/10.1183/09031936.00098411
Lee JS, Giesler DL, Gellad WF, Fine MJ. Antibiotic therapy for adults hospitalized with community-acquired pneumonia: a systematic review. Jama 2016;315(6):593-602. DOI: https://doi.org/10.1001/jama.2016.0115
Lodise TP, Kwa A, Cosler L, Gupta R, Smith RP. Comparison of β-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia. Antimicrobial agents and chemotherapy, 2007; 51(11): 3977-82. DOI: https://doi.org/10.1128/AAC.00006-07
Gündüz C, Taşbakan MS, Sayıner A, Çilli A, Kilinç O, Şakar Coşkun A. Factors affecting treatment success in community-acquired pneumonia. Turk J Med Sci 2016; 46:1469-1474. DOI: https://doi.org/10.3906/sag-1502-87
Cataudella E, Giraffa CM, Di Marca S, Pulvirenti A, Alaimo S, Pisano M, Terranova V, Corriere T, Ronsisvalle ML, Di Quattro R, Stancanelli B, Giordano M, Vancheri C, Malatino L. Neutrophil‐to‐lymphocyte ratio: An emerging marker predicting prognosis in elderly adults with community‐acquired pneumonia. J Am Geriatrics Society 2017;65(8):1796-1801. DOI: https://doi.org/10.1111/jgs.14894
Ugajin M, Yamaki K, Yagi T, Asano T. Blood urea nitrogen to serum albumin ratio independently predicts mortality and severity of community-acquired pneumonia. Int J Gen Med. 2012;5:583-89. DOI: https://doi.org/10.2147/IJGM.S33628
Felmingham D, Canton R, Jenkins SG. Regional trends in beta-lactam, macrolide, fluoroquinolone and telithromycin resistance among Streptococcus pneumoniae isolates 2001-2004. J Infect 2007;55:111-8. DOI: https://doi.org/10.1016/j.jinf.2007.04.006
Simonetti AF, van Werkhoven CH, Schweitzer VA, Viasus D, Carratala J, Postma DF, Oosterheert JJ, Bonten MJM. Predictors for individual patient antibiotic treatment effect in hospitalized community-acquired pneumonia patients. Clin Microbiol Infect 2017;23(10):774-e1. DOI: https://doi.org/10.1016/j.cmi.2017.03.010
Doruk S, Tertemiz KC, Kömüs N, Uçan ES, Kilinç O, Sevinç C. Community acquired pneumonia and direct hospital cost. Tuberk Toraks 2009;57(1):48-55.
Raz-Pasteur A, Shasha D, Paul M. Fluoroquinolones or macrolides alone versus combined with β-lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis. Intern J Antimicr Agents 2015;46(3):242-8. DOI: https://doi.org/10.1016/j.ijantimicag.2015.04.010
Çilli A, Sayıner A, Çelenk B, Şakar Coşkun A, Kılınç O, Hazar A, Aktaş Samur A, Taşbakan S, Waterer GW, Havlucu Y, Kılıç Ö, Tokgöz F, Bilge U. Antibiotic treatment outcomes in community-acquired pneumonia. Turk J Med Sci 2018;48:730-36. DOI: https://doi.org/10.3906/sag-1709-144
Bircan A, Kaya O, Gökirmak M, Ozturk O, Sahin U, Akkaya A. C-reactive protein, leukocyte count and ESR in the assessment of severity of community-acquired pneumonia. Tuberk Toraks, 2006;54(1):22-29.
Coelho L, Póvoa P, Almeida E. Usefulness of C-reactive protein in monitoring the severe community-acquired pneumonia clinical course. Crit Care 2007;11:R92. DOI: https://doi.org/10.1186/cc6105
Angkananard T, Anothaisintawee T, McEvoy M, Attia J, Thakkinstian A. Neutrophil Lymphocyte Ratio and Cardiovascular Disease Risk: A Systematic Review and Meta-Analysis. BioMed Res Int 2018:2703518. DOI: https://doi.org/10.1155/2018/2703518
Tokgoz Akyil F, Yalcinsoy M, Hazar A, Cilli A, Celenk B, Kilic O, Sayıner A, Kokturk N, Sakar Coskun A, Filiz A, Cakır Edis E. Prognosis of hospitalized patients with community-acquired pneumonia. Pulmonology 2018, 24.3: 164-169. DOI: https://doi.org/10.1016/j.rppnen.2017.07.010
Drent M, Cobben NA, Henderson RF, Wouters EF, van-Dieijen-Visser M. Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation. Eur Respir J 1996;9(8):1736-42. DOI: https://doi.org/10.1183/09031936.96.09081736
Miyashita N, Kawai Y, Inamura N, Tanaka T, Akaike H, Teranishi H, Wakabayashi T, Nakano T, Ouchi K, Okimoto N. Setting a standard for the initiation of steroid therapy in refractory or severe Mycoplasma pneumoniae pneumonia in adolescents and adults. J. Infect Chemother 2015;21:153–160. DOI: https://doi.org/10.1016/j.jiac.2014.10.008
Nicolini A, Ferraioli G, Ferrari‐Bravo m, Barlascini C, Santo M, Ferrara L. Early non‐invasive ventilation treatment for respiratory failure due to severe community‐acquired pneumonia. Clin Resp J 2016;10(1):98-103. DOI: https://doi.org/10.1111/crj.12184
Downloads
Published
How to Cite
Issue
Section
License
With the licence CC-BY, authors retain the copyright, allowing anyone to download, reuse, re-print, modify, distribute, and/or copy their contribution. The work must be properly attributed to its author.
It is not necessary to ask for further permission from the author or journal board.
This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.